Savara (NASDAQ:SVRA) Stock Jumps 7.2% – Still a Buy?

Savara Inc. (NASDAQ:SVRA)’s share price traded up 7.2% during mid-day trading on Wednesday. The stock traded as high as $5.05 and last traded at $4.9850. 360,182 shares changed hands during trading, a decline of 78% from the average session volume of 1,671,651 shares. The stock had previously closed at $4.65.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on SVRA shares. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. JPMorgan Chase & Co. started coverage on shares of Savara in a report on Wednesday. They issued an “overweight” rating and a $12.00 target price for the company. Finally, Citigroup reissued a “market outperform” rating on shares of Savara in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.25.

Savara Stock Down 1.0%

The stock has a fifty day moving average of $5.33 and a 200 day moving average of $5.41. The firm has a market capitalization of $992.37 million, a P/E ratio of -8.33 and a beta of 0.20. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, research analysts anticipate that Savara Inc. will post -0.61 EPS for the current fiscal year.

Institutional Trading of Savara

Large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. purchased a new position in Savara in the first quarter valued at about $57,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Savara during the 2nd quarter worth approximately $69,000. E Fund Management Co. Ltd. bought a new stake in shares of Savara in the 2nd quarter worth approximately $77,000. Sanctuary Advisors LLC bought a new stake in shares of Savara in the 2nd quarter worth approximately $87,000. Finally, Inceptionr LLC purchased a new position in Savara in the first quarter valued at approximately $84,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.